GENOLUTION INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,030 KRW | +0.25% |
|
+1.51% | +5.08% |
| 01-09 | Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023. | CI |
| 01-09 | Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023. | CI |
| Sales 2021 | 72.83B 53.46M 4.29B | Sales 2022 | 38.08B 27.95M 2.24B | Capitalization | 87.18B 63.99M 5.14B |
|---|---|---|---|---|---|
| Net income 2021 | 34.39B 25.25M 2.03B | Net income 2022 | 14.6B 10.72M 860M | EV / Sales 2021 | 1.48 x |
| Net cash position 2021 | 43.56B 31.98M 2.57B | Net cash position 2022 | 29.49B 21.65M 1.74B | EV / Sales 2022 | 1.51 x |
| P/E ratio 2021 |
2.17
x | P/E ratio 2022 |
2.9
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 69.11% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.25% | ||
| 1 week | +1.51% | ||
| Current month | -0.12% | ||
| 1 month | +7.90% | ||
| 3 months | +3.20% | ||
| 6 months | +8.04% | ||
| Current year | +5.08% |
1 week
3 955.00
4 065.00
1 month
3 480.004 500.00
Current year
3 480.004 715.00
1 year
3 480.006 040.00
3 years
3 480.0010 891.09
5 years
1 141.0913 118.81
10 years
1 000.0013 118.81
| Managers | Title | Age | Since |
|---|---|---|---|
Ki-Ok Kim
CEO | Chief Executive Officer | 69 | 31/01/06 |
Yong-Ho Cho
DFI | Director of Finance/CFO | 50 | 31/05/21 |
Min-Ee Kim
CTO | Chief Tech/Sci/R&D Officer | 38 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hak-Soo Lee
BRD | Director/Board Member | 67 | 19/03/20 |
Ki-Ok Kim
CEO | Chief Executive Officer | 69 | 31/01/06 |
In-Jun Kim
BRD | Director/Board Member | 71 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/05/24 | 4,030 | +0.25% | 27,802 |
| 02/05/24 | 4,020 | -0.37% | 42,076 |
| 30/04/24 | 4,035 | +0.12% | 25,218 |
| 29/04/24 | 4,030 | +1.51% | 69,520 |
| 26/04/24 | 3,970 | +1.66% | 60,658 |
End-of-day quote Korea S.E., May 02, 2024
More quotes
GENOLUTION INC. is a company principally engaged in the manufacture and distribution of molecular diagnostic equipment and products related ribonucleic acid interference (RNAi) research. The Companyâs products include automated nucleic acid extraction devices, nucleic acid extraction reagents and molecular diagnostic products. The Company also provides ribonucleic acid interference services. The Company distributes its products within domestic market and to overseas markets.
Calendar
07/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +5.08% | 57.09M | |
| -16.10% | 11.41B | |
| -30.20% | 2.3B | |
| -14.31% | 2.16B | |
| -26.03% | 1.56B | |
| +36.95% | 1.19B | |
| -2.40% | 760M | |
| -19.00% | 506M | |
| -38.57% | 444M | |
| +13.72% | 339M |
- Stock Market
- Equities
- A225220 Stock
